Shanghai Jinhe Bio-Technology Co., Ltd. is a high Bio-Tech private enterprise dedicated to developing, manufacturing and marketing Anti-Cancer APIs and their intermediates.

Jinhe was established in March 2002. Based on the R&D achievement of FUDAN university, at the beginning it launched the international business of processing Paclitaxel API. After severalyears of development, we has been emerging as the largest processor on Taxus biomass in China. Afterwards, we successfully developed Docetaxel Anhydrous( Trihydrate), Irinotecan HCl Trihydrate, Etoposide and other products, developing Anti-cancer products from nature extracting to semi-synthetical Anti-cancer products. In recent two years we additionally developed Fludarabine Phosphate, Palonosetron Hydrochloride and so on, developed Anti-cancer from botanical raw materials to broad-spectrum Anti-cancer drug